Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + thalidomide
- Development stage
- Unknown
- Lead developer
- Case Comprehensive Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
docetaxel + thalidomide is a combination chemotherapy and immunomodulatory regimen investigated by the Case Comprehensive Cancer Center. This combination pairs docetaxel, a taxane small molecule that stabilizes microtubules to inhibit cell division, with thalidomide, an immunomodulatory drug (IMiD) known for its anti-angiogenic and anti-inflammatory properties. The regimen was specifically studied in a Phase I dose-escalation trial using a metronomic (low-dose, frequent) administration of docetaxel to enhance the anti-angiogenic synergy with thalidomide. It was targeted toward patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma who had progressed on standard therapies.
- Other names
- docetaxel + thalidomidethalidomide + docetaxelThalidomide and Docetaxel
02
Targets
CRBN (Cereblon)TUBB (Tubulin (alpha and beta subunits))FGFR2 (Keratinocyte growth factor receptor)TNFA (Tumor necrosis factor alpha (soluble))IKZF1 (Ikaros family zinc finger protein 1)
Beyond the preview
Go deeper on docetaxel + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + thalidomide.